NLS Pharmaceutics Ltd. (NCEL)
Market Closed
30 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
3. 36
-0.16
-4.5057%
$
1.69M Market Cap
- P/E Ratio
- Div Yield
9,730 Volume
- Eps
$ 3.52
Previous Close Investors:
Want to track NCEL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
NCEL closed today lower at $3.36, a decrease of -4.5057% from yesterday's close, completing a monthly decrease of -14.9013% or -$0.59. Over the past 12 months, NCEL stock gained 68.9146%.
NCEL is not paying dividends to its shareholders.
The last earnings report, released on Feb 25, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
NLS Pharmaceutics Ltd. has completed 2 stock splits, with the recent split occurring on Oct 31, 2025.
The company's stock is traded on one exchange.
NLS Pharmaceutics Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 3 | $5.7 | $11.91 | $6.21 | 108.95% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $2.12 | $3.97 | $1.85 | 87.26% |
NLS Pharmaceutics Ltd. (NCEL) FAQ
What is the stock price today?
The current price is $3.36.
On which exchange is it traded?
NLS Pharmaceutics Ltd. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is NCEL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.69M.
Has NLS Pharmaceutics Ltd. ever had a stock split?
NLS Pharmaceutics Ltd. had 2 splits and the recent split was on Oct 31, 2025.
NLS Pharmaceutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ronen Twito CEO | NASDAQ (CM) Exchange | H5835A109 CUSIP |
| CH Country | 11 Employees | - Last Dividend | 31 Oct 2025 Last Split | - IPO Date |
Overview
NewcelX Ltd. is a pioneering biotechnology firm established in 2008, with its headquarters located in Zurich, Switzerland. The company focuses on the innovative development of cell-based therapies and small-molecule therapies aimed at addressing neurodegenerative and metabolic diseases. By leveraging cutting-edge technology and scientific research, NewcelX aspires to create transformative treatments that could change the standards of care in these challenging medical fields.
Products and Services
- Cell-Based Therapies: NewcelX develops advanced cell-based therapies designed to repair or replace damaged cells in the body, specifically targeting conditions associated with neurodegenerative diseases. These therapies utilize the latest cellular technology to promote healing and restore function in affected areas.
- Small-Molecule Therapies: The company is also engaged in the discovery and development of small-molecule therapies that modulate cellular functions and signaling pathways. These therapies aim to provide effective treatment options for metabolic disorders, enhancing the management of diseases at a molecular level.
- Research and Development: NewcelX invests significantly in research and development, focusing on the discovery of novel compounds and therapeutic approaches. Their dedicated team of scientists and researchers collaborate to uncover new possibilities for treating complex diseases through innovative strategies.
- Collaborative Partnerships: The company actively seeks partnerships with academic institutions, research organizations, and other biotechnology companies. These collaborations enhance their capability to innovate and expedite the development of their therapies, ultimately benefiting patients with limited options.
- Clinical Trials: NewcelX conducts rigorous clinical trials to assess the safety and efficacy of their therapies. Through this systematic evaluation process, the company aims to ensure that their products meet the highest standards of quality and effectiveness before they are brought to market.
- Regulatory Compliance: The company prioritizes adherence to regulatory guidelines and standards in all aspects of its operations. By ensuring compliance with regulatory requirements, NewcelX seeks to facilitate the approval process for its innovative therapies, bringing them to patients as quickly and safely as possible.
Contact Information
Address: The Circle 6
Phone: 972 73 797 1600
Website: https://newcelx.net
